From: Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
Patient # | Duration of crizotinib (days) | No: of Cysts during study period | Mixed pattern of evolution of lesions | New cysts | Enlarged from baseline | Stable during study period | Regressed from baseline | ||
---|---|---|---|---|---|---|---|---|---|
Then regressed | Ongoing enlargement | ||||||||
CR | PR | ||||||||
1 | 280 | 2 | Y | 0 | 1 | 1 | |||
2 | 1344 | 1 | N | 0 | 1 | ||||
3 | 678 | 2 | Y | 0 | 1 | 1; CR | |||
4 | 126 | 5 | Y | 4 | (+4) | 1 | |||
5 | 686 | 4 | Y | 0 | 1 | 2 | 1; PR | ||
6 | 150 | 3 | Y | 0 | 1 | 2 | |||
7 | 547 | 1 | N | 0 | 1 | ||||
8 | 1109 | 4 | Y | 1 | 2 (+1) | 1 | |||
9 | 160 | 2 | Y | 1 | (1) | 1 | |||
10 | 1477 | 1 | N | 0 | 1 | ||||
11 | 1456 | 3 | Y | 2 | 1(+2) | ||||
Median age 48 years; 45% F; 64% Asian | Median 678 | 28 | 4/11 patients | 13/28 cysts | 4/28 cysts | 2/28 cysts | 7/28 cysts | 2/28 cysts |